Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tarceva plus Gemcitabine as first-line treatment in unresectable advanced/metastatic non-small cell lung cancer
2007-002135-83Phase 2Completed
- Sponsor
- Roche
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Roche. Primary endpoints: Time to disease progression (TTP) and Pathological response rate (CR, PR). Started Feb 2017; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2007-002135-83.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002135-83.